Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What will Jimenez and the new structure bring to Novartis?

This article was originally published in Scrip

Executive Summary

Change at the top of Novartis has been on the cards for a while. The company had been expected to separate the roles of chairman and CEO, and Daniel Vasella, who has been at the helm for 14 years, was expected to step aside. These changes are now in place, along with some surprises at the top.

You may also be interested in...



2010 Scrip 100 - Pharma muscles into emerging markets with M&A

This year has seen many firms facing patent expiries on core revenue generators. The current climate is driving M&A strategies, particularly in emerging markets and often with a focus on branded generics. Abbott has used M&A to propel itself to the top of the Indian market, writes Karen Beynon.

2010 Scrip 100 - US healthcare reform timeline

The debate surrounding reform of the US healthcare system dominated headlines throughout 2009. Here are some of the landmark events of the past 12 months.

2010 Scrip 100 - Japan price cuts to sting at home and abroad

Pharmaceutical companies are bracing themselves for Japan's next round of drug price cuts, due in April 2010. Faced with shrinking margins at home, Japanese firms are refocusing their efforts on rapidly expanding Asian and stable western markets to prop up their bottom lines. Will Japanese pharma lose its taste for innovation, asks Karen Beynon.

Topics

Related Companies

UsernamePublicRestriction

Register

SC006636

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel